KRAS and cancer: As previously reported and confirmed here, ADT-007 selectively induces apoptosis of KRAS-mutant cancer cells, which may be a key advantage over mutant-specific KRAS and other pan-KRAS or pan-RAS inhibitors approved or in development by circumventing resistance [35].